Lantheus (LNTH) will publish its quarterly results on Thursday
Lantheus (NASDAQ:LNTH – Get a rating) will announce its results before the market opens on Thursday, August 4. Analysts expect the company to report earnings of $0.64 per share for the quarter. Lantheus set its guidance for the second quarter at $0.67-0.73 EPS and its guidance for FY22 at $2.90-3.15 EPS. Investors interested in participating in the company’s conference call can do so using this link.
Lantheus (NASDAQ:LNTH – Get a rating) last released its quarterly earnings data on Friday, April 29. The medical equipment supplier reported EPS of $0.97 for the quarter, beating the consensus estimate of $0.41 by $0.56. The company posted revenue of $208.90 million in the quarter, versus a consensus estimate of $165.30 million. Lantheus posted a positive return on equity of 19.83% and a negative net margin of 6.89%. The company’s revenue increased by 125.8% compared to the same quarter last year. During the same period of the previous year, the company achieved EPS of $0.05. On average, analysts expect Lantheus to post EPS of $3 for the current fiscal year and EPS of $3 for the next fiscal year.
Lantheus stock up 4.7%
NASDAQ:LNTH shares opened at $74.14 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.83 and a debt ratio of 0.31. The company has a fifty-day moving average of $66.40 and a two-hundred-day moving average of $53.39. The stock has a market capitalization of $5.09 billion, a P/E ratio of -130.07 and a beta of 0.75. Lantheus has a 52-week low of $22.20 and a 52-week high of $75.09.
Analysts set new price targets
Several analysts have published reports on the company. Truist Financial raised its target price on Lantheus from $77.00 to $94.00 in a Monday, May 2 report. B. Riley began coverage of Lantheus in a report on Monday, May 9. They issued a “buy” rating and a target price of $91.00 for the company. StockNews.com began covering Lantheus in a report on Thursday, March 31. They set a “hold” rating for the company. Finally, SVB Leerink reiterated an “outperform” rating and set a $100.00 price target on Lantheus shares in a Monday, June 6 report.
Insider Trading at Lantheus
In other news, CAD Andrea Sabens sold 1,093 shares in a trade on Monday, July 18. The stock was sold at an average price of $71.47, for a total transaction of $78,116.71. Following completion of the transaction, the chief accounting officer now directly owns 63,162 shares of the company, valued at approximately $4,514,188.14. The transaction was disclosed in a document filed with the SEC, accessible via the SEC website. In related news, CAD Andrea Sabens sold 1,093 shares of the company in a transaction dated Monday, July 18. The stock was sold at an average price of $71.47, for a total transaction of $78,116.71. Following completion of the transaction, the chief accounting officer now directly owns 63,162 shares of the company, valued at approximately $4,514,188.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Also, CEO Marie Anne Heino sold 12,276 shares of the company in a transaction dated Monday, May 9. The shares were sold at an average price of $61.19, for a total value of $751,168.44. As a result of the transaction, the CEO now owns 695,115 shares of the company, valued at $42,534,086.85. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 26,798 shares of the company worth $1,676,307. 1.60% of the shares are currently held by insiders of the company.
Hedge funds weigh on Lantheus
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can increased its holdings in Lantheus by 1.7% in Q1. Bank of Montreal Can now owns 18,279 shares of the medical equipment supplier valued at $1,026,000 after acquiring 303 additional shares during the period. Yousif Capital Management LLC increased its position in Lantheus by 1.8% in the 1st quarter. Yousif Capital Management LLC now owns 61,853 shares of the medical equipment supplier valued at $3,421,000 after purchasing an additional 1,086 shares last quarter. PNC Financial Services Group Inc. increased its position in Lantheus by 30.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,721 shares of the medical equipment supplier valued at $261,000 after buying 1,099 additional shares last quarter. American Century Companies Inc. increased its position in Lantheus by 14.4% in the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment supplier valued at $1,064,000 after buying 2,427 additional shares last quarter. Finally, Fairfield Bush & CO. acquired a new stake in Lantheus in Q1 valued at approximately $177,000. 97.14% of the shares are currently held by hedge funds and other institutional investors.
Lantheus Company Profile
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic products that aid clinicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound examinations of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess lung function; Neurolite to identify the area of the brain where blood flow has been blocked or reduced due to a stroke; Cardiolite, a Tc-99m labeled injectable imaging agent; Thallium-201 to detect cardiovascular diseases; and Gallium-67 to detect various infections and cancerous tumors.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Should you invest $1,000 in Lantheus right now?
Before you consider Lantheus, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Lantheus wasn’t on the list.
Although Lantheus currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here